TC-DAPK 6
Based on 15 publication(s) in Google Scholar
TC-DAPK 6 is a potent, ATP-competitive, and highly selective DAPK inhibitor (IC50=69 and 225 nM against DAPK1 and DAPK3, respectively, with 10 μM ATP).
For research use only. We do not sell to patients.
- Purity: 96.87%
- CAS No.: 315694-89-4
- Formula: C17H12N2O2
- Molecular Weight:276.29
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Kinase Inhibitor Library
HY-L009
-
Targeted Diversity Library
HY-L099
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
Kinase Inhibitor Library Mini
HY-L009M
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) TC-DAPK 6
More- Mol Neurodegener. 2025 Nov 21;20(1):121. [Abstract]
- Theranostics. 2022 May 9;12(8):3847-3861. [Abstract]
- Theranostics. 2020 Sep 15;10(25):11479-11496. [Abstract]
- Biol Psychiatry. 2019 May 1;85(9):769-781. [Abstract]
- J Transl Med. 2025 Nov 4;23(1):1220. [Abstract]
- Cancer Cell Int. 2024 Nov 18;24(1):382. [Abstract]
- Chem Biol Interact. 2026 Jun 1:432:112053. [Abstract]
- J Mol Med (Berl). 2019 Jan;97(1):89-102. [Abstract]
- Cancer Sci. 2020 Aug;111(8):2803-2813. [Abstract]
- Sci Rep. 2018 Jul 2;8(1):9930. [Abstract]
- Exp Neurol. 2020 Jul:329:113303. [Abstract]
- Lab Invest. 2019 Jul;99(8):1143-1156. [Abstract]
- Biochem Biophys Res Commun. 2024 Sep 10:724:150216. [Abstract]
- Friedrich Schiller University Jena. 2026.
- Dis Markers. 2022 Jan 17:2022:9651092. [Abstract]
Customer Validation & Images
-
WB
Biological Activity
IC50: 69 nM (DAPK1), 225 nM (DAPK3)[1]
TC-DAPK 6 is found to be the most potent Death-associated protein kinase (DAPK) inhibitor with enzyme selectivity. When assayed with 10 μM ATP, the IC50 values for DAPK1 and DAPK3 are 69 and 225 nM, respectively. TC-DAPK 6 also inhibits p70S6K (1 μM < IC50< 10 μM)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 315694-89-4
-
Appearance Solid
-
Molecular Weight 276.29
-
Formula C17H12N2O2
-
Color Light yellow to yellow
-
SMILES
O=C(OC(/C=C/C1=CC=CC=C1)=N/2)C2=C/C3=CC=CN=C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (15)
-
Journal Impact Factor
-
Most Recent
-
Mol Neurodegener
Death-associated protein kinase 1-dependent SENP1 degradation increases tau SUMOylation and leads to cognitive dysfunction in a mouse model for tauopathy. [Abstract]2025 Nov 21;20(1):121. PMID: 41272902 -
Theranostics
PTBP1 knockdown promotes neural differentiation of glioblastoma cells through UNC5B receptor. [Abstract]2022 May 9;12(8):3847-3861. PMID: 35664063 -
Theranostics
Redox DAPK1 destabilizes Pellino1 to govern inflammation-coupling tubular damage during septic AKI. [Abstract]2020 Sep 15;10(25):11479-11496. PMID: 33052227 -
Biol Psychiatry
MicroRNA-26a/Death-Associated Protein Kinase 1 Signaling Induces Synucleinopathy and Dopaminergic Neuron Degeneration in Parkinson's Disease. [Abstract]2019 May 1;85(9):769-781. PMID: 30718039 -
J Transl Med
DAPK1-positve macrophages facilitate immunosuppressive microenvironment and determine immunotherapy efficacy in colorectal cancer. [Abstract]2025 Nov 4;23(1):1220. PMID: 41188869 -
Cancer Cell Int
DAPK enhances DDX20 protein stability via suppression of TRIM25-mediated ubiquitination-based DDX20 degradation. [Abstract]2024 Nov 18;24(1):382. PMID: 39558224 -
Chem Biol Interact
Quercetin inhibits adipogenesis and promotes adipose tissue remodeling through lipophagy-mediated lipid droplet (LD) clearance. [Abstract]2026 Jun 1:432:112053. PMID: 41864473 -
J Mol Med (Berl)
Downregulation of DAPK1 promotes the stemness of cancer stem cells and EMT process by activating ZEB1 in colorectal cancer. [Abstract]2019 Jan;97(1):89-102. PMID: 30460377 -
Cancer Sci
Death-associated protein kinase 1 suppresses hepatocellular carcinoma cell migration and invasion by upregulation of DEAD-box helicase 20. [Abstract]2020 Aug;111(8):2803-2813. PMID: 32449268 -
Sci Rep
Death-associated protein kinase 1 mediates interleukin-1β production through regulating inlfammasome activation in Bv2 microglial cells and mice. [Abstract]2018 Jul 2;8(1):9930. PMID: 29967321
TC-DAPK 6 purchased from MedChemExpress. Usage Cited in: Sci Rep. 2018 Jul 2;8(1):9930. [Abstract]
The effects of DAPK1 inhibitor (10 μM) treatment on the expression of p-MLC, caspase-1, NLRP3, pro-IL-1β and ASC in LPS-primed cells are determined by western blotting analysis.
-
Exp Neurol
Presynaptic Caytaxin prevents apoptosis via deactivating DAPK1 in the acute phase of cerebral ischemic stroke. [Abstract]2020 Jul:329:113303. PMID: 32277960 -
Lab Invest
Activation of death-associated protein kinase 1 promotes neutrophil apoptosis to accelerate inflammatory resolution in acute respiratory distress syndrome. [Abstract]2019 Jul;99(8):1143-1156. PMID: 30911150 -
Biochem Biophys Res Commun
2024 Sep 10:724:150216. PMID: 38851140 -
-
Dis Markers
Death-Associated Protein Kinase 1 (DAPK1) Protects against Myocardial Injury Induced by Myocardial Infarction in Rats via Inhibition of Inflammation and Oxidative Stress. [Abstract]2022 Jan 17:2022:9651092. PMID: 35082934
Solvent & Solubility
DMSO : 18.67 mg/mL (67.57 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2 mg/mL (7.24 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Kinase assay is performed using the Z’-LYTE kinase assay kit Ser/Thr 13 peptide. The standard reaction for compound screening contained 1 mM peptide substrate, 10 mM ATP, 50 mM HEPES (pH 7.4), 10 mM MgCl2, 0.01% Brij-35, and 0.5% DMSO. Human recombinant DAPK1 is used at a final concentration of 2.6 μg/mL, and recombinant DAPK3 is used at a final concentration 1.5 mg/mL. To test the enzyme selectively of the inhibitors (e.g., TC-DAPK 6), ProfilerPro kits are used in the protocol[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.6194 mL | 18.0969 mL | 36.1939 mL | 90.4846 mL |
| 5 mM | 0.7239 mL | 3.6194 mL | 7.2388 mL | 18.0969 mL | |
| 10 mM | 0.3619 mL | 1.8097 mL | 3.6194 mL | 9.0485 mL | |
| 15 mM | 0.2413 mL | 1.2065 mL | 2.4129 mL | 6.0323 mL | |
| 20 mM | 0.1810 mL | 0.9048 mL | 1.8097 mL | 4.5242 mL | |
| 25 mM | 0.1448 mL | 0.7239 mL | 1.4478 mL | 3.6194 mL | |
| 30 mM | 0.1206 mL | 0.6032 mL | 1.2065 mL | 3.0162 mL | |
| 40 mM | 0.0905 mL | 0.4524 mL | 0.9048 mL | 2.2621 mL | |
| 50 mM | 0.0724 mL | 0.3619 mL | 0.7239 mL | 1.8097 mL | |
| 60 mM | 0.0603 mL | 0.3016 mL | 0.6032 mL | 1.5081 mL |
TC-DAPK 6 Related Classifications
HY-15513 Related Classifications
Powered by Bioz